Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

Adrienne G. Waks, Jingxin Fu, Xiangying Chu, Busem Binboga Kurt, Tianyu Li, Thomas Kuntz, Yizhuo Shen, David D. Yang, Kevin Meli, Brendan Reardon, Jihye Park, Ann H. Partridge, Daniel L. Abravanel, Rinath Jeselsohn, Eileen Wrabel, Jillian Alberti, Molly DiLullo, S. Chen, Ayesha Mohammed-Abreu, Xiaopeng Sun, Justin M. Balko, Miranda Kleijn, William Audeh, Xochitl C. Morgan, Ian E. Krop, Nabihah Tayob, Eliezer M. Van Allen, Elizabeth A. Mittendorf, Sara M. TolaneyNature Communications 2025 · DOI

Abstract

Patients with hormone receptor-positive (HR+)/HER2- breast cancer may benefit from neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy. The effect of chemotherapy or ICI run-in before combination therapy in this population is unexplored. In this randomized pilot trial, patients with HR+/HER2- breast cancer received two weeks of neoadjuvant nab-paclitaxel or pembrolizumab, with baseline and post-run-in tumor biopsy, followed by combined nab-paclitaxel/pembrolizumab. The primary endpoint was PD-L1 expression change between biopsies. Tumor whole exome/RNA sequencing were performed. Of 29 patients, 72% were node-positive. Residual cancer burden (RCB) 0-1 rate was 28% (inclusive of patients receiving additional neoadjuvant adriamycin/cyclophosphamide). No significant change in PD-L1 expression occurred following nab-paclitaxel or pembrolizumab run-in, thus the primary endpoint was not met. Other secondary outcome measures included overall response rate of 80% to the neoadjuvant regimen, and 3-year event-free survival of 86% (95% CI 69-100%); there were no unexpected safety signals. In exploratory biomarker analyses, higher baseline PD-L1 expression and inflammatory gene signatures were associated with favorable response (RCB 0-1); higher expression of estrogen response genes, with unfavorable response (RCB 2-3).

Introduction

Hormone receptor-positive (HR+), HER2-negative breast cancer is the most common subtype of the disease, yet it remains "immunologically cold" compared to triple-negative breast cancer. These tumors typically exhibit lower PD-L1 expression, fewer tumor-infiltrating lymphocytes (TILs), and a lower mutational burden, making them less responsive to immune checkpoint inhibitors (ICIs). This randomized pilot trial, published in Nature Communications, investigated whether a short "run-in" phase of either chemotherapy or immunotherapy could prime the tumor microenvironment to enhance the efficacy of subsequent combination treatment.

Methods

The study (NCT02999477) was a randomized, open-label pilot trial involving 29 evaluable patients with stage II/III HR+/HER2- breast cancer. Patients were randomized 1:1 to receive a two-week run-in of either nab-paclitaxel (Arm A) or pembrolizumab (Arm B). Following the run-in and a second biopsy, all patients received combined nab-paclitaxel and pembrolizumab. Serial biopsies (baseline, week 3, and week 7) were analyzed using whole-exome sequencing (WES), RNA-seq, and immunohistochemistry for PD-L1 and TILs.

Trial schema showing the randomized run-in phases of nab-paclitaxel or pembrolizumab followed by combination therapy.

Key Results

The primary endpoint of the trial was the change in tumor cell PD-L1 H-score between baseline and post-run-in biopsies. The study failed to meet this endpoint, as neither chemotherapy nor ICI monotherapy significantly boosted PD-L1 expression or TIL levels during the two-week window (p = 1.00).

Despite the lack of microenvironmental "priming," the trial provided significant clinical and molecular insights:

  • Clinical Efficacy: The overall response rate (ORR) was 80%, and the 3-year event-free survival was 86%. The pathologic complete response (pCR) rate was 17% (5/29 patients).
  • PD-L1 as a Predictor: pCR rates were markedly higher in patients with baseline PD-L1 Combined Positive Score (CPS) ≥ 10 (43%) compared to those with lower expression.
Pathologic complete response (pCR) rates stratified by baseline PD-L1 Combined Positive Score (CPS).
  • Estrogen and Immune Suppression: High expression of estrogen response genes was strongly associated with unfavorable response (Residual Cancer Burden 2-3). Mechanistically, high estrogen signaling correlated with decreased antigen processing and presentation, effectively shielding the tumor from the immune system.
  • Inflammatory Signatures and Gut Microbiome: Favorable responses (RCB 0-1) were associated with baseline enrichment in interferon-alpha/gamma and TNF-alpha signaling. Furthermore, exploratory analysis identified gut microbial pathways—specifically arginine and nucleotide synthesis—as strong predictors of response.

Discussion

The failure of the run-in phase to significantly alter PD-L1 expression suggests that the "order of operations" for these agents may be less impactful than hypothesized, or that a longer window is required for observable shifts. However, the identification of estrogen signaling as a major driver of immunotherapy resistance provides a clear roadmap for future research. Combining ICIs with endocrine therapy or targeting the metabolic pathways identified in the gut microbiome may offer new avenues for treating HR+ breast cancer. While limited by a small sample size, this trial offers a high-resolution multi-omic map of the factors dictating immunotherapy response in this challenging subtype.

Summary updated

Abstract

Patients with hormone receptor-positive (HR + )/HER2- breast cancer may benefit from neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy. The effect of chemotherapy or ICI run-in before combination therapy in this population is unexplored. In this randomized pilot trial, patients with HR + /HER2- breast cancer received two weeks of neoadjuvant nab-paclitaxel or pembrolizumab, with baseline and post-run-in tumor biopsy, followed by combined nab-paclitaxel/pembrolizumab. The primary endpoint was PD-L1 expression change between biopsies. Tumor whole exome/RNA sequencing were performed. Of 29 patients, 72% were node-positive. Residual cancer burden (RCB) 0-1 rate was 28% (inclusive of patients receiving additional neoadjuvant adriamycin/cyclophosphamide). No significant change in PD-L1 expression occurred following nab-paclitaxel or pembrolizumab run-in, thus the primary endpoint was not met. Other secondary outcome measures included overall response rate of 80% to the neoadjuvant regimen, and 3-year event-free survival of 86% (95% CI 69-100%); there were no unexpected safety signals. In exploratory biomarker analyses, higher baseline PD-L1 expression and inflammatory gene signatures were associated with favorable response (RCB 0-1); higher expression of estrogen response genes, with unfavorable response (RCB 2-3). Clinical Trial Number: NCT02999477.
BibTeX
@inproceedings{waks2025efficacy,
  author = {Adrienne G. Waks and Jingxin Fu and Xiangying Chu and Busem Binboga Kurt and Tianyu Li and Thomas Kuntz and Yizhuo Shen and David D. Yang and Kevin Meli and Brendan Reardon and Jihye Park and Ann H. Partridge and Daniel L. Abravanel and Rinath Jeselsohn and Eileen Wrabel and Jillian Alberti and Molly DiLullo and S. Chen and Ayesha Mohammed-Abreu and Xiaopeng Sun and Justin M. Balko and Miranda Kleijn and William Audeh and Xochitl C. Morgan and Ian E. Krop and Nabihah Tayob and Eliezer M. Van Allen and Elizabeth A. Mittendorf and Sara M. Tolaney},
  title = {{Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial}},
  booktitle = {Nature Communications},
  year = {2025},
  doi = {10.1038/s41467-025-66667-y},
}
Figure